Friday Hope: Caffeine: Blood-Brain Barrier Protection and SARS-CoV-2 Therapeutic Properties https://t.co/DTXE9IDUey
— St. Michael, the Archangel (@aveng_angel) February 17, 2024
Okay, so COVID-19 as well as the COVID-19 gene therapy shots disrupt the blood-brain barrier, BBB. Well, then isn't there some food, some therapeutic that would protect the blood-brain barrier? Yes, there is. Caffeine. That's right, your morning cup of joe.
Given the recent study showing that SARS-CoV-2 disrupts the Blood-Brain Barrier (BBB), I stated that I would search for therapeutics that help to protect the BBB and ward against neurodegenerative diseases. I found one such therapeutic that not only helps to protect the BBB but is also useful against SARS-CoV-2. This is none other than Caffeine.
Find sources here.
CAFFEINE PROTECTS AGAINST ALZHEIMER'S DISEASE, AD
Caffeine protects the integrity of the blood-brain barrier.
Recent epidemiological and experimental studies indicate that caffeine, when administered chronically, has beneficial effects against a number of acute and chronic neurological disorders including stroke, AD, and PD. For AD, the protective effects of caffeine have been observed in humans as well as in animal models of this neurodegenerative disorder. Epidemiologically, chronic ingestion of caffeine conferred protective effects against AD and a retrospective study showed that caffeine intake is associated with a significantly lower risk for AD. Prospective studies confirmed the above findings by showing that chronic caffeine intake improved memory and cognitive function in normal aged individuals as well as in AD patients. Subsequently, experimental studies conducted using animal models of AD noted that caffeine improved cognitive abilities, reduced Aβ production, and stabilized BBB integrity. Thus, caffeine and drugs like caffeine might be part of any regimen intended to prevent, delay, and/or treat AD.
BBB PROTECTING ASPECT OF CAFFEINE MAY ALSO TREAT PARKINSON'S SYMPTOMS
epidemiologic studies demonstrated that caffeine when administered chronically decreased the risk of developing PD. Experimental studies confirmed and extended the epidemiological findings by showing that caffeine was neuroprotective against the loss of dopaminergic neurons that occurs in the substantial nigra of MPTP-treated mice. Thus, current evidence strongly suggests that caffeine is a promising agent in the prevention and/or treatment of PD.
